CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Sitagliptin compared with the Sulfonylurea Glimepiride provides similar efficacy with less Hypoglycemia and no weight gain when added to ongoing Metformin therapy in patients with Type 2 Diabetes Mellitus (T2DM)
DOI 10.1055/s-0030-1253887
Bibliografische Angaben
Nachweis in CareLit
Autor:innenT Seck, DE Williams-Herman, Y Chen, L Duran, AO Johnson-Levonas, KD Kaufman, BJ Goldstein
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe04/2010
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Question: Current guidelines recommend the addition of another antihyperglycemic agent when glycemic control is not achieved with metformin monotherapy. Sulfonylureas are the most common antihyperglycemic agents used in combination with metformin among patients who do not achieve or maintain glycemic control on metformin alone. In previous studies, the DPP-4 inhibitor sitagliptin (SITA) significantly improved glycem…
Zitieren
Zitierempfehlung
T Seck, DE Williams-Herman, Y Chen, L Duran, AO Johnson-Levonas, KD Kaufman, BJ Goldstein (2010) Sitagliptin compared with the Sulfonylurea Glimepiride provides similar efficacy with less Hypoglycemia and no weight gain when added to ongoing Metformin therapy in patients with Type 2 Diabetes Mellitus (T2DM). Diabetologie und Stoffwechsel (04). https://doi.org/10.1055/s-0030-1253887
Mit CareLit weiterarbeiten